Vectus Biosystems

Vectus Biosystems Net Change in Cash

The Net Change in Cash of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is 467,606.00 AUD. In the previous year, Net Change in Cash was -557,981.00 AUD — a change of -183.80% (higher).

Net Change in Cash

467,606.00AUD

YoY

-183.80%

Last updated:

Net Change in Cash of Vectus Biosystems is 2026 467,606.00 AUD. Net Change in Cash of Vectus Biosystems was 2025 -557,981.00 AUD. It decreases by -183.80% higher compared to the previous year.

The Vectus Biosystems Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
1,361.00 AUD
Jan 1, 2020
2.64 M AUD
Jan 1, 2021
3.09 M AUD
Jan 1, 2022
-4.50 M AUD
Jan 1, 2023
1.67 M AUD
Jan 1, 2024
-2.14 M AUD
Jan 1, 2025
-557,981.00 AUD
Jan 1, 2026
467,606.00 AUD
The Vectus Biosystems Net Change in Cash history
YEARNet Change in CashYoY
467,606.00AUD-183.80%
-557,981.00AUD-73.95%
-2.14 MAUD-228.29%
1.67 MAUD-137.13%
-4.50 MAUD-245.39%
3.09 MAUD+17.06%
2.64 MAUD+194,030.12%
1,361.00AUD-100.29%
-475,101.00AUD-593.49%
96,273.00AUD-104.46%
-2.16 MAUD-204.09%
2.07 MAUD-363.94%
-785,860.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Net Change in Cash of Vectus Biosystems is 467,606.00 AUD in 2026.

Net Change in Cash of Vectus Biosystems changed from -557,981.00 AUD to 467,606.00 AUD, representing a -183.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Vectus Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vectus Biosystems

All Key Metrics — Vectus Biosystems